Recoflavone - Dong-A ST
Alternative Names: DA-6034; GLH8NDELatest Information Update: 15 Apr 2024
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A Pharmaceutical; Dong-A ST
- Class Anti-inflammatories; Antiallergics; Benzopyrans; Eye disorder therapies; Flavonoids; Small molecules
- Mechanism of Action Antioxidants; Calcium channel agonists; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Dry eyes; Gastritis
Highest Development Phases
- Phase III Gastritis
- Phase II Dry eyes
- Discontinued Crohn's disease; Ulcerative colitis
Most Recent Events
- 22 Dec 2020 GL Pharm Tech Corporation plans a phase II trial in Dry eyes in April 2021 (Ophthalmic, Drops) (NCT04679883)
- 23 Jul 2020 Phase-I development is ongoing in South Korea in Dry eyes (NCT04104997)
- 18 Feb 2020 GL Pharm Tech completes a phase I trial in Dry eyes (In volunteers) in South Korea (Ophthalmic, Drops) (NCT04104997)